Jim Simons
MLYS icon

Jim Simons’s Mineralys Therapeutics MLYS Stock Holding History

Jim Simons’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
378,300
-4,500
-1% -$123K 0.01% 1047
2026
Q1 		$10.4M Buy
382,800
+60,700
+19% +$1.78M 0.02% 950
2025
Q4 		$11.7M Buy
322,100
+274,700
+580% +$11M 0.02% 841
2025
Q3 		$1.8M Sell
47,400
-129,526
-73% -$2.8M ﹤0.01% 2142
2025
Q2 		$2.39M Sell
176,926
-374
-0.2% -$5.42K ﹤0.01% 2001
2025
Q1 		$2.82M Buy
177,300
+57,800
+48% +$665K ﹤0.01% 1781
2024
Q4 		$1.47M Buy
119,500
+15,700
+15% +$205K ﹤0.01% 2258
2024
Q3 		$1.26M Buy
103,800
+42,000
+68% +$508K ﹤0.01% 2308
2024
Q2 		$723K Buy
61,800
+30,100
+95% +$379K ﹤0.01% 2504
2024
Q1 		$409K Buy
31,700
+6,200
+24% +$76.6K ﹤0.01% 2951
2023
Q4 		$219K Sell
25,500
-70,190
-73% -$551K ﹤0.01% 3105
2023
Q3 		$910K Buy
+95,690
New +$1.25M ﹤0.01% 2375

Other funds holding MLYS

Catalys Pacific
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Samsara BioCapital
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.6B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jim Simons's MLYS Position: Q2 2026 in Review

Jim Simons reduced its Mineralys Therapeutics (MLYS) stake by 1.2% in Q2 2026, selling an estimated $123K and leaving 378,300 shares worth $10.2M. The position accounts for 0.01% of the portfolio, ranked #1047.

Jim Simons first reported a position in MLYS in Q3 2023 and has held it in 12 quarters since. The position peaked at $11.7M in Q4 2025. 225 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Jim Simons held 378,300 shares of Mineralys Therapeutics worth $10.2M as of Q2 2026.
  • Jim Simons sold 4,500 Mineralys Therapeutics shares in Q2 2026, an estimated $123K.
  • Mineralys Therapeutics made up 0.01% of Jim Simons's portfolio in Q2 2026, its #1047 holding.
  • Jim Simons first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Jim Simons's Mineralys Therapeutics position peaked at $11.7M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.